John K.  Clarke net worth and biography

John Clarke Biography and Net Worth

Director of aTyr Pharma
Mr. Clarke is managing general partner of Cardinal Partners. He entered the venture industry in 1982 with DSV Partners, a pioneer venture capital fund formed in 1968. John led DSV’s health care and life sciences efforts and was a co-founder and served as interim CEO of numerous successful companies including Alkermes, Arris Pharmaceuticals, DNX and Cubist Pharmaceuticals. As managing partner at DSV in later years, Mr. Clarke led the firm’s evolution into Cardinal Partners. Building on two decades in venture capital, he co-founded Cardinal Partners in 1997. He currently serves on the Board of Directors of Alnylam Pharmaceuticals, Momenta Pharmaceuticals, Rib-X Pharmaceuticals and Verastem . He has also served as a director for Sirtris Pharmaceuticals (acquired by GlaxoSmithKline), TechRx (acquired by NDCHealth) and Visicu (acquired by Phillips Electronics). Mr. Clarke is also a Trustee of Hands Together, a non-profit organization that provides health care and education support to the needy in Haiti. Prior to his venture capital career, John worked for the General Electric Company in various sales and marketing positions. Mr. Clarke received his A.B. in economics and biology from Harvard University and his M.B.A. from the Wharton School at the University of Pennsylvania.

What is John K. Clarke's net worth?

The estimated net worth of John K. Clarke is at least $0.00 as of May 21st, 2021. Mr. Clarke owns 7,492 shares of aTyr Pharma stock worth more than $0 as of November 21st. This net worth approximation does not reflect any other investments that Mr. Clarke may own. Learn More about John K. Clarke's net worth.

How do I contact John K. Clarke?

The corporate mailing address for Mr. Clarke and other aTyr Pharma executives is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. aTyr Pharma can also be reached via phone at (858) 731-8389 and via email at [email protected]. Learn More on John K. Clarke's contact information.

Has John K. Clarke been buying or selling shares of aTyr Pharma?

John K. Clarke has not been actively trading shares of aTyr Pharma during the last ninety days. Most recently, John K. Clarke sold 2,500 shares of the business's stock in a transaction on Friday, May 21st. The shares were sold at an average price of $4.34, for a transaction totalling $10,850.00. Following the completion of the sale, the director now directly owns 7,492 shares of the company's stock, valued at $32,515.28. Learn More on John K. Clarke's trading history.

Who are aTyr Pharma's active insiders?

aTyr Pharma's insider roster includes Jill Broadfoot (CFO), John Clarke (Director), Paul Schimmel (Director), and Sanjay Shukla (CEO). Learn More on aTyr Pharma's active insiders.

Are insiders buying or selling shares of aTyr Pharma?

In the last twelve months, aTyr Pharma insiders bought shares 4 times. They purchased a total of 78,000 shares worth more than $136,160.00. The most recent insider tranaction occured on May, 31st when CFO Jill Marie Broadfoot bought 5,000 shares worth more than $8,950.00. Insiders at aTyr Pharma own 3.7% of the company. Learn More about insider trades at aTyr Pharma.

Information on this page was last updated on 5/31/2024.

John K. Clarke Insider Trading History at aTyr Pharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/21/2021Sell2,500$4.34$10,850.007,492View SEC Filing Icon  
9/2/2020Sell7,260$4.01$29,112.607,492View SEC Filing Icon  
8/28/2020Sell100$4.00$400.007,492View SEC Filing Icon  
8/26/2020Sell2,200$4.30$9,460.007,492View SEC Filing Icon  
See Full Table

John K. Clarke Buying and Selling Activity at aTyr Pharma

This chart shows John K Clarke's buying and selling at aTyr Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

aTyr Pharma Company Overview

aTyr Pharma logo
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $1.76
Low: $1.57
High: $2.07

2 Week Range

Now: N/A

Volume

269,400 shs

Average Volume

514,103 shs

Market Capitalization

$131.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19